Compare Equinor ASA (EQNR) vs Pfizer Inc (PFE) Price & Performance

Equinor (EQNR) trades at $38.92, down 1.37% over the past day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 21.32% ROE and attractive valuation metrics, including a P/E of 10.55 and EV/EBITDA of 2.19. Recent Q2 2026 earnings missed estimates, but revenue grew 40% year-over-year, supported by higher energy prices and production. The company continues shareholder returns via dividends and a share buy-back program.

EQNR presents a mixed outlook: robust cash flow and strategic investments in subsea projects support growth, but declining net income margins and geopolitical energy market volatility pose risks. Analyst consensus is cautious with 30.43% buy ratings, reflecting fair valuation concerns after recent gains. The stock offers value through dividends and buybacks, yet investors face exposure to oil price swings and execution risks in capital projects.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.